| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1001 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 0069-1002 | XELJANZ | tofacitinib | Pfizer Laboratories Div Pfizer Inc | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-012 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |
| 63539-016 | XELJANZ | tofacitinib | U.S. Pharmaceuticals | NDA | Current |